Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹66,818 Cr
Revenue (TTM)
₹31,724 Cr
Net Profit (TTM)
₹3,486 Cr
ROE
11.2 %
ROCE
13.8 %
P/E Ratio
19.2
P/B Ratio
2
Industry P/E
38.59
EV/EBITDA
9.2
Div. Yield
0 %
Debt to Equity
0
Book Value
₹562.2
EPS
₹59.9
Face value
1
Shares outstanding
580,801,623
CFO
₹27,088.72 Cr
EBITDA
₹41,053.60 Cr
Net Profit
₹26,604.69 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| -13.8 | -4.6 | 3.8 | -7.9 | 29.2 | 8.3 | 6.1 |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
BSE Healthcare
| -2.6 | 5.8 | 11.7 | 19.7 | 25.9 | 22.2 | 11.0 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
| 23.5 | 147.3 | -40.3 | -20.8 | 101.1 | -37.7 | 7.2 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
|
1,150.2 | 66,818.3 | 31,723.7 | 3,515.3 | 15.5 | 11 | 19.2 | 2.0 |
| 31,515.0 | 66,790.2 | 6,409.2 | 1,414.4 | 25.3 | 36.5 | 47.2 | 15.8 | |
| 4,847.5 | 57,725.4 | 12,964.5 | 2,216.0 | 16.6 | 18.4 | 26.7 | 4.8 | |
| 1,505.2 | 1,21,216.8 | 27,547.6 | 5,291.1 | 21.9 | 17.7 | 23 | 3.9 | |
| 1,362.5 | 1,13,001.4 | 32,643.9 | 5,703.5 | 20.7 | 17.6 | 20 | 3.4 | |
| 1,999.6 | 91,339.1 | 22,707.9 | 3,306.3 | 18.0 | 20 | 27.8 | 5.3 | |
| 2,381.3 | 98,107.7 | 12,279.3 | 1,998.9 | 19.6 | 16 | 49.3 | 6.8 | |
| 1,687.8 | 4,03,892.1 | 52,578.4 | 10,980.1 | 23.3 | 16.2 | 37 | 5.6 | |
| 3,252.5 | 1,10,070.9 | 11,516.0 | 1,911.0 | 25.4 | 25.6 | 57.6 | 14.5 | |
| 975.0 | 97,982.0 | 23,241.5 | 4,614.8 | 26.2 | 20.4 | 21.7 | 4.1 |
6 min read•By Yash Rohra
4 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and... over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Read more
Incorporated
1986
Chairman
M Ramasubramanian
Managing Director
K Nithyananda Reddy
Group
Aurobindo
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Aurobindo Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Aurobindo Pharma Ltd stood at ₹ 49,785 Cr as on 31-Mar-25
The share price of Aurobindo Pharma Ltd is ₹1,150.20 (NSE) and ₹1,150.65 (BSE) as of 13-Jun-2025 15:58 IST. Aurobindo Pharma Ltd has given a return of 29.18% in the last 3 years.
Aurobindo Pharma Ltd has a market capitalisation of ₹ 66,818 Cr as on 13-Jun-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Aurobindo Pharma Ltd is 2.05 times as on 13-Jun-2025, a 63% discount to its peers’ median range of 5.60 times.
The P/E ratio of Aurobindo Pharma Ltd is 19.17 times as on 13-Jun-2025, a 50% discount to its peers’ median range of 38.59 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aurobindo Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Aurobindo Pharma Ltd.
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
The prominent promoters of Aurobindo Pharma Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) |
33.5%
|
|
KAMBAM NITYANANDA REDDY |
4.37%
|
|
KIRTHI REDDY KAMBAM |
3.45%
|
The chairman of the company is M Ramasubramanian, and the managing director is K Nithyananda Reddy.
The promoters of Aurobindo Pharma Ltd have pledged 8.77% of the total equity as on Mar-25.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,03,076
|
|
|
1,21,456
|
|
|
1,10,197
|
|
|
1,06,761
|
|
|
97,097
|
|
|
96,598
|
|
|
91,303
|
|
|
67,469
|
|
|
58,168
|
| Aurobindo Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
10.97
|
|
Operating margin(%)
|
15.47
|
|
Net Margin(%)
|
10.86
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Aurobindo Pharma Ltd was ₹3,486 Cr.
₹-5.00
(
